Unison Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Unison Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.76M	Buy	6,035 +6	+0.1%	+$4.08K	0.26%	49
2026 Q1	$4.66M	Buy	6,029 +6	+0.1%	+$4.59K	0.35%	31
2025 Q4	$4.65M	Buy	6,023 +8	+0.1%	+$5.43K	0.41%	31
2025 Q3	$3.38M	Buy	6,015 +9	+0.1%	+$5.09K	0.31%	42
2025 Q2	$3.15M	Buy	6,006 +8	+0.1%	+$4.46K	0.35%	41
2025 Q1	$3.8M	Hold	5,998	–	–	0.48%	36
2024 Q4	$4.27M	Hold	5,998	–	–	0.51%	31
2024 Q3	$6.31M	Hold	5,998	–	–	0.76%	20
2024 Q2	$6.3M	Hold	5,998	–	–	0.79%	17
2024 Q1	$5.77M	Hold	5,998	–	–	0.57%	21
2023 Q4	$5.27M	Hold	5,998	–	–	0.56%	19
2023 Q3	$4.94M	Hold	5,998	–	–	0.58%	16
2023 Q2	$4.31M	Hold	5,998	–	–	0.48%	21
2023 Q1	$4.93M	Hold	5,998	–	–	0.55%	17
2022 Q4	$4.33M	Hold	5,998	–	–	0.56%	19
2022 Q3	$4.13M	Hold	5,998	–	–	0.77%	16
2022 Q2	$3.55M	Hold	5,998	–	–	0.91%	19
2022 Q1	$4.19M	Hold	5,998	–	–	1.01%	12
2021 Q4	$3.79M	Hold	5,998	–	–	0.92%	22
2021 Q3	$3.63M	Sell	5,998 -1,548	-21%	-$961K	0.91%	15
2021 Q2	$4.21M	Buy	+7,546	New	+$3.82M	0.79%	16

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Unison Advisors's REGN Position: Q2 2026 in Review

Unison Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 0.1% in Q2 2026, buying an estimated $4.08K and bringing the position to 6,035 shares worth $3.76M. The position accounts for 0.26% of the portfolio, ranked #49.

Unison Advisors first reported a position in REGN in Q2 2021 and has held it in 21 quarters since. The position peaked at $6.31M in Q3 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Unison Advisors held 6,035 shares of Regeneron Pharmaceuticals worth $3.76M as of Q2 2026.
Unison Advisors bought 6 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.08K.
Regeneron Pharmaceuticals made up 0.26% of Unison Advisors's portfolio in Q2 2026, its #49 holding.
Unison Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
Unison Advisors's Regeneron Pharmaceuticals position peaked at $6.31M in Q3 2024.
1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Unison Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.